Tocilizumab explored as second-line therapy in steroid-resistant pediatric TED

Tocilizumab as second-line therapy was found to be an effective tool in the management of steroid-resistant thyroid eye disease (TED) in a pediatric patient, according to a case report. When severe TED is steroid-resistant in children it can be difficult to manage. A single case report has shown the effectiveness...